For example, melanomas harboring mutations of driver events in the MAPK pathway (BRAF, NRAS, NF1, KIT, and so on) have been shown to respond well to MEK/MAPK inhibitors (2, 14–26). The gene discussed is BRAF; the disease is melanoma.